Downstaging Advanced Hepatocellular Carcinoma to the Milan Criteria May Provide a Comparable Outcome to Conventional Milan Criteria

Journal of Gastrointestinal Surgery

Volumn 17, Issue 8, 2013, Pages 1440-1446

  Lei, Jianyong ^a   Wang, Wentao ^a   Yan, Lunan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Downstage; Hepatocellular carcinoma; Liver; Transplant

Indexed keywords

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER STAGING; CATHETER ABLATION; CHEMOEMBOLIZATION; DISEASE FREE SURVIVAL; FEMALE; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVER TUMOR; MALE; MIDDLE AGED; PATHOLOGY; PATIENT SELECTION; RADIOSURGERY; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; DISEASE-FREE SURVIVAL; FEMALE; HIGH-INTENSITY FOCUSED ULTRASOUND ABLATION; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PATIENT SELECTION; RADIOSURGERY; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84880135422     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-013-2229-y     Document Type: Article

References (38)

1. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002;35: S72-S78.
2. Rossi L, Zoratto F, Papa A, Iodice F, et al. Current approach in the treatment of hepatocellular carcinoma. World J Gastrointest Oncol 2010;2: 348-359.
3. Gordon-Weeks AN, Snaith A, Petrinic T, et al. Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria. Br J Surg. 2011 Sep;98(9): 1201-8.
4. Parkin M, Bray F, Ferlay J, et al. Global cancer statistics. 2002. CA Cancer J Clin. 2005;55: 74-108.
5. Lei JY, Yan LN. Outcome comparisons among the Hangzhou, Chengdu and UCSF criteria for hepatocellular carcinoma liver transplantation after successful down-staging therapies. J Gastrointest Surg 2013 Jan 17. [Epub ahead of print].
6. Belghiti J, Carr BI, Greig PD, et al. Treatment before liver transplantation for HCC. Ann Surg Oncol. 2008 Apr;15(4): 993-1000.
7. Penn I. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery 1991;110: 726-734.
8. Pichlmayr R, Weimann A, Ringe B. Indication for liver transplantation in hepatobiliary malignancy. Hepatology 1994;20: 338-408.
9. Ringe B, Pichlmayr R, Wittekind C, et al. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg. 1991;15: 270.
10. Bismuth H, Chiche L, Adam R, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991;214: 221.
11. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334: 693-699.
12. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellur carcinoma: expansion of the tumor size limites does not adversely impact survival. Hepatology. 2001;6: 1394-1403.
13. Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, Liang TB, Wu LM. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008;85: 1726-1732.
14. Lei JY, Yan LN. Comparison between living donor liver transplantation recipients who met the Milan and UCSF criteria after successful downstaging therapies. J Gastrointest Surg. 2012 Nov; 16(11): 2120-5.
15. Klintmalm GB, liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg 1998;228: 479-490.
16. Yokoyama I, Todo S, Iwatsuki S, Starzl TE. Liver transplantation in the treatment of primary liver cancer. Hepatogastroenterology 1990;37: 188-193.
17. Yao FY, Kerlan RK Jr, Hirose R, et al. excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology. 2008; 48(3): 819-27.
18. Chapman WC, Majella Doyle MB, Stuart JE, et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 2008;248: 617-625.
19. De Luna W, Sze D, Ahened A, Ha BY, et al. Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Am J Transplant 2009;9: 1158-1168.
20. Cillo U, Vitale A, Grigoletto F, et al. Intention-to-treat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding the Milan criteria. Am J Transplant 2007;7: 972-981.
21. Otto G, Herber S, Heise M, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006;12: 1260-1267.
22. Graziadei IW, Sandmueller H, Waldenberger P, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003;9: 557-563.
23. Yao FY. Expanding criteria for hepatocellular carcinoma: down-staging with a view to liver transplantation- yes. Smmin Liver Diseas 2006;26: 239-247.
24. Bruix J, Sherman M, Liovet J, et al. Clinical management of hepatocellular carcinoma. Conclusion do the Barcellona-2000 EASL conference. J Hepatol 2001;35: 4210-4230.
25. Bruix J, Sherman M. Practice Guidelines Committee, American association for the study of liver diseases. Management of hepatocellular carcinoma. Hepatology 2005;42: 1208-1236.
26. Marsh JW, Dvorchik I, Iwatsuki S. UNOS policy in upgrading patients with HCC awaiting liver transplantation: too little too late. Transplantation 2000;69(Supple): S139.
27. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30: 52-60.
28. Edeline J, Boucher E, Rolland Y et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer. 2012;118: 147-156.
29. Yao FY, Xiao L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF expanded criteria based on pre-operative imaging. Am J Transpl 2007;7: 2587-2596.
30. Ravaioli M, Grazi GL, Piscaglia F, et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 2008, 8(12): 2547-57.
31. Millonig G, Graziadei IW, Freund MC, et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007;13: 272-279.
32. Barakat O, Wood RP, Ozaki CF, et al. Morphological features of advanced hepatocellular carcinoma as a predictor of down-staging and liver transplantation: and intention-to-treat analysis. Liver Transpl 2010;16: 289-299.
33. Yao FY, Breitenstein S, Broelsch CE, et al. Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma? Liver Transpl. 2011;17 Suppl 2: S109-16.
34. Majno PE, Adam R, Bismuth H, et al. influence of preoperative transarterial lipodol chemombolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997;226: 688-701.
35. Shi XJ, Jin X, Wang MQ, et al. Outcomes of loco-regional therapy for down-staging of hepatocellular carcinoma prior to liver transplantation. Hepatobiliary Pancreat Dis Int. 2011;10(2): 143-50.
36. Liovet JM, Schwartz M, Fuster J, Bruix J. Expand criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: not yet there. Semin Liver Dis. 2006 Aug;26(3): 248-53.
37. Nissen NN, Menon V, Bresee C, et al. Recurrent hepatocellular carcinoma after liver transplant: identifying the high-risk patient. HPB(Oxford). 2011;13(9): 626-32.
38. Bertuzzo VR, Cescon M, Ravaioli M, et al. Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers. Transplantation. 2011;91(11): 1279-85.